
16/09/2025
Semaglutide. Tirzepatide.
The names dominate headlines: “Game-changing weight loss injections.” “A revolution in diabetes care.”
But beyond the buzz, here’s what the evidence says:
Glycemic control: Landmark trials (SURPASS, SUSTAIN) show significant A1C reductions.
Weight loss: Up to 10–15% average reduction in obesity trials.
Cardiovascular protection: SUSTAIN-6 & LEADER confirm fewer major adverse events.
Challenges remain: Cost, access, and long-term safety beyond 5–10 years need more data.
Verdict:
Neither miracle nor hype. GLP-1 therapies, when prescribed for the right patient at the right time, represent one of the most important advances in diabetes and obesity care in decades.
What’s your view—paradigm shift or overstatement?